Investors sold shares of Bioverativ Inc (NASDAQ:BIVV) on strength during trading on Tuesday. $17.11 million flowed into the stock on the tick-up and $95.23 million flowed out of the stock on the tick-down, for a money net flow of $78.12 million out of the stock. Of all stocks tracked, Bioverativ had the 6th highest net out-flow for the day. Bioverativ traded up $0.10 for the day and closed at $103.70
Several brokerages have recently weighed in on BIVV. Morgan Stanley raised shares of Bioverativ from an “underweight” rating to an “equal weight” rating in a report on Tuesday, January 23rd. Jefferies Group downgraded shares of Bioverativ from a “buy” rating to a “hold” rating in a report on Monday, January 22nd. Piper Jaffray Companies downgraded shares of Bioverativ from an “overweight” rating to a “neutral” rating in a report on Monday, January 22nd. Raymond James Financial downgraded shares of Bioverativ from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 23rd. Finally, Credit Suisse Group reissued a “neutral” rating on shares of Bioverativ in a report on Wednesday, January 24th. Thirteen equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $63.15.
The firm has a market capitalization of $11,230.00 and a price-to-earnings ratio of 25.35.
Hedge funds have recently added to or reduced their stakes in the stock. Robeco Institutional Asset Management B.V. purchased a new stake in Bioverativ during the fourth quarter worth about $105,000. American Assets Investment Management LLC acquired a new position in Bioverativ during the fourth quarter worth about $108,000. Advisors Asset Management Inc. acquired a new position in Bioverativ during the third quarter worth about $137,000. TCI Wealth Advisors Inc. acquired a new position in Bioverativ during the third quarter worth about $186,000. Finally, Ladenburg Thalmann Financial Services Inc. acquired a new position in Bioverativ during the third quarter worth about $190,000. 94.10% of the stock is currently owned by hedge funds and other institutional investors.
Bioverativ Company Profile
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.